2025
Utility and Outcomes of Ovarian Tissue Cryopreservation and Transplantation for Gynecologic Cancers: A Systematic Review and Meta-analysis
Erden M, Gayete-Lafuente S, Vural N, Oktay K. Utility and Outcomes of Ovarian Tissue Cryopreservation and Transplantation for Gynecologic Cancers: A Systematic Review and Meta-analysis. Obstetrical & Gynecological Survey 2025, 80: 350-351. DOI: 10.1097/ogx.0000000000001414.Peer-Reviewed Original ResearchCyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers
Kim D, Chung H, Liu W, Jeong K, Ozmen T, Ozmen F, Rames M, Kim S, Guo X, Jameson N, de Jong P, Yea S, Harford L, Li J, Mathews C, Doroshow D, Charles V, Kim D, Fischer K, Samatar A, Jubb A, Bunker K, Blackwell K, Simpkins F, Meric-Bernstam F, Mills G, Harismendy O, Ma J, Lackner M. Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. Npj Precision Oncology 2025, 9: 3. PMID: 39755818, PMCID: PMC11700143, DOI: 10.1038/s41698-024-00787-4.Peer-Reviewed Original ResearchUterine serous carcinomaSerous carcinomaCyclin E1 expressionOvarian cancer cell linesWEE1 kinase inhibitionE1 expressionPhase I studyClasses of chemotherapyUpregulation of cyclin E1Levels of replication stressIn vivo modelsCancer cell linesGynecologic malignanciesGynecologic cancerOncogenic driversCell cycle checkpointsClinical activityG1 to S phaseBaseline levelsMultiple cell cycle checkpointsActivity of CDK2Cell cycle progressionKinase inhibitionCell linesCyclin E1
2024
Estimating the population-level impact of a platinum chemotherapy shortage on patients with gynecologic cancers in the United States cost-effectiveness of investing in the supply chain
Albright B, Wallbillich J, Lightfoot M, Mattei L, Polan R, Kailasam A, Aviki E, Saiz A, Spencer R, Havrilesky L, Shahin M, Fader A, Secord A, Myers E, Ko E. Estimating the population-level impact of a platinum chemotherapy shortage on patients with gynecologic cancers in the United States cost-effectiveness of investing in the supply chain. Gynecologic Oncology 2024, 190: s340-s341. DOI: 10.1016/j.ygyno.2024.07.510.Peer-Reviewed Original ResearchSupply chainGynecologic cancerUtility and Outcomes of Ovarian Tissue Cryopreservation and Transplantation for Gynecologic Cancers
Erden M, Gayete-Lafuente S, Vural N, Oktay K. Utility and Outcomes of Ovarian Tissue Cryopreservation and Transplantation for Gynecologic Cancers. Obstetrics And Gynecology 2024, 144: 481-492. PMID: 39173181, PMCID: PMC11499045, DOI: 10.1097/aog.0000000000005708.Peer-Reviewed Original ResearchCryopreserved ovarian tissue transplantationOvarian tissue cryopreservationOvarian tissue transplantationTissue cryopreservationAutologous transplantationGynecologic cancerTissue transplantationOutcome of autologous transplantationPreserving ovarian functionCochrane Library databasesOvarian endocrine functionPooled-effect estimatesSystematic reviewRisk-of-bias assessmentOvarian stimulationHematologic malignanciesLonger-term outcomesFertility preservationOvarian functionBreast cancerLibrary databasesTransplantationGraft longevityCancerEndocrine functionRacial and ethnic differences in epithelial ovarian cancer risk: an analysis from the Ovarian Cancer Association Consortium
Meagher N, White K, Wilkens L, Bandera E, Berchuck A, Carney M, Cramer D, Cushing-Haugen K, Jordan S, Kaufmann S, Le N, Pike M, Riggan M, Qin B, Rothstein J, Titus L, Winham S, Anton-Culver H, Doherty J, Goode E, Pearce C, Risch H, Webb P, Cook L, Goodman M, Harris H, Le Marchand L, McGuire V, Pharoah P, Sarink D, Schildkraut J, Sieh W, Terry K, Thompson P, Whittemore A, Wu A, Peres L, Merritt M. Racial and ethnic differences in epithelial ovarian cancer risk: an analysis from the Ovarian Cancer Association Consortium. American Journal Of Epidemiology 2024, 193: 1242-1252. PMID: 38775277, PMCID: PMC11369223, DOI: 10.1093/aje/kwae076.Peer-Reviewed Original ResearchConceptsOvarian Cancer Association ConsortiumEpithelial ovarian cancer riskNative Hawaiian/Pacific IslanderEpithelial ovarian cancerInverse associationHawaiian/Pacific IslanderRisk associationOdds ratioOvarian cancer riskRisk factor associationsTubal ligationLogistic regression modelsOral contraceptive (OCIslander womenCancer riskFactor associationsWhite participantsPrevention strategiesAsian womenOC useEthnic differencesRisk factorsGynecologic cancerRegression modelsOvarian cancerARID1A in Gynecologic Precancers and Cancers
Morgan J, Jaferi N, Shonibare Z, Huang G. ARID1A in Gynecologic Precancers and Cancers. Reproductive Sciences 2024, 31: 2150-2162. PMID: 38740655, DOI: 10.1007/s43032-024-01585-w.Peer-Reviewed Original ResearchARID1A alterationsGynecologic cancerTumor suppressor ARID1AResponse to chemotherapeutic agentsFrequency of genetic alterationsLoss-of-function mutationsSWI/SNF complex subunitsFemale reproductive tractFunction of ARID1ARadiation therapyTumor-suppressive actionAtypical hyperplasiaARID1A mutationsARID1A deficiencyTherapeutic vulnerabilitiesChemotherapeutic agentsGenetic alterationsImmune modulationClinical evidenceARID1ASignaling pathway interactionsSuppressive actionEndoplasmic reticulumProtein expressionCancer895 The utility, safety and outcomes of ovarian tissue cryopreservation for gynecologic cancers: an analysis from a large fertility preservation program and systematic review of the literature
Erden M, Gayete-Lafuente S, Vural N, Oktay K. 895 The utility, safety and outcomes of ovarian tissue cryopreservation for gynecologic cancers: an analysis from a large fertility preservation program and systematic review of the literature. International Journal Of Gynecological Cancer 2024, 34: a243-a244. DOI: 10.1136/ijgc-2024-esgo.473.Peer-Reviewed Original Research
2023
Adoption of cytoreductive surgery in the management of peritoneal malignancies—Global trends
Sedighim S, Khan A, Li A, Tajik F, Radhakrishnan V, Eng O, Turaga K, Senthil M. Adoption of cytoreductive surgery in the management of peritoneal malignancies—Global trends. Journal Of Surgical Oncology 2023, 128: 1021-1031. PMID: 37818906, DOI: 10.1002/jso.27448.Peer-Reviewed Original ResearchTimeliness of diagnostic evaluation for postmenopausal bleeding: A retrospective cohort study using claims data
Xu X, Chen L, Nunez-Smith M, Clark M, Wright J. Timeliness of diagnostic evaluation for postmenopausal bleeding: A retrospective cohort study using claims data. PLOS ONE 2023, 18: e0289692. PMID: 37682914, PMCID: PMC10490884, DOI: 10.1371/journal.pone.0289692.Peer-Reviewed Original ResearchConceptsPostmenopausal bleedingFirst diagnostic procedureDiagnostic evaluationDiagnostic proceduresGynecologic conditionsMedicaid patientsCox proportional hazards modelPrompt diagnostic evaluationRetrospective cohort studyMarketScan Research DatabasesAdditional risk factorsNon-clinical factorsCommon gynecologic conditionProportional hazards modelLower ratesCohort studyMost patientsPatient characteristicsBenign etiologyGynecologic cancerCancer patientsPreventive careUterine cancerInsurance typeRisk factorsA phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1).
Winer I, Patnaik A, Barve M, Kummar S, Schenk E, LoRusso P, Yeku O, Fu S, Jahchan N, Myers M, Liang L, Deegan D, Jackson L, Li Y, Reyno L, Chamberlain M. A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1). Journal Of Clinical Oncology 2023, 41: 2523-2523. DOI: 10.1200/jco.2023.41.16_suppl.2523.Peer-Reviewed Original ResearchSingle agentDose levelsNon-small cell lung cancerAdvanced refractory solid tumorsDose-escalation study designImmune-related adverse eventsTriple-negative breast cancerImmune checkpoint inhibitorsAcceptable safety profileDose-escalation studyRefractory solid tumorsCell lung cancerArchival tumor tissueEnrollment of subjectsImmune-related reactionsDose proportionalECOG PSRECIST 1.1Stable diseaseTREM1 expressionCheckpoint inhibitorsAdverse eventsPartial responseRadiographic responseGynecologic cancer
2022
Advances in antibody-drug conjugates for gynecologic malignancies
Tymon-Rosario J, Gorman M, Richardson D, Washington C, Santin A. Advances in antibody-drug conjugates for gynecologic malignancies. Current Opinion In Obstetrics & Gynecology 2022, 35: 6-14. PMID: 36484278, DOI: 10.1097/gco.0000000000000838.Peer-Reviewed Original ResearchConceptsAntibody-drug conjugatesOvarian cancer patientsGynecologic malignanciesCancer patientsPlatinum-resistant ovarian cancer patientsUse of ADCsOngoing phase 3 trialsRecurrent ovarian cancer patientsNovel antibody-drug conjugateReceptor-targeting antibodiesPhase 3 trialProgression-free survivalFirst U.S. FoodOngoing clinical trialsHER2/neuPersonalized cancer careTisotumab vedotinPrimary endpointCervical cancerGynecologic cancerCancer careClinical trialsMultiple tumorsCurrent evidenceDrug AdministrationHealth Disparities in Uterine Cancer
Whetstone S, Burke W, Sheth SS, Brooks R, Cavens A, Huber-Keener K, Scott DM, Worly B, Chelmow D. Health Disparities in Uterine Cancer. Obstetrics And Gynecology 2022, 139: 645-659. PMID: 35272301, PMCID: PMC8936152, DOI: 10.1097/aog.0000000000004710.Peer-Reviewed Original ResearchConceptsHealth care cliniciansUterine cancerWomen's health care cliniciansHealth disparitiesEvidence-based educational materialsCare cliniciansGynecologic cancerEvidence summariesGynecologic oncologyPractice guidelinesEarly diagnosisAmerican CollegeGeneral obstetricsEvidence reviewDisease controlCancerPanel of expertsSubstantive knowledge gapsEducational materialsCliniciansPreventionContent expertsLiterature reviewRelevant literatureReviewExecutive Summary of the Uterine Cancer Evidence Review Conference
Chelmow D, Brooks R, Cavens A, Huber-Keener K, Scott DM, Sheth SS, Whetstone S, Worly B, Burke W. Executive Summary of the Uterine Cancer Evidence Review Conference. Obstetrics And Gynecology 2022, 139: 626-643. PMID: 35272316, PMCID: PMC8936160, DOI: 10.1097/aog.0000000000004711.Peer-Reviewed Original ResearchConceptsHealth care cliniciansUterine cancerEarly diagnosisWomen's health care cliniciansEvidence-based educational materialsCare cliniciansGynecologic cancerEvidence summariesGynecologic oncologyPatient advocacy organizationsPractice guidelinesAmerican CollegeGeneral obstetricsPanel membersEvidence reviewDisease controlPanel of expertsSubstantive knowledge gapsCancerCliniciansRelevant literaturePreventionEducational materialsDiagnosisContent experts
2021
Financial toxicity in patients with gynecologic malignancies: a cross sectional study
Zeybek B, Webster E, Pogosian N, Tymon-Rosario J, Balch A, Altwerger G, Clark M, Menderes G, Huang G, Azodi M, Ratner ES, Schwartz PE, Santin AD, Andikyan V. Financial toxicity in patients with gynecologic malignancies: a cross sectional study. Journal Of Gynecologic Oncology 2021, 32: e87. PMID: 34431257, PMCID: PMC8550931, DOI: 10.3802/jgo.2021.32.e87.Peer-Reviewed Original ResearchConceptsCross-sectional studyGynecologic malignanciesFinancial toxicityPatient demographicsSectional studyMalignancy typeGynecologic oncology patientsOvarian cancer patientsPatient/diseaseCost of careFinancial burdenHigh financial burdenTreatment regimenHigh financial toxicityOncology patientsDisease characteristicsGynecologic cancerCancer careCancer patientsRisk factorsClinical trialsCOST scoreMedian COST scorePatientsSignificant burden
2020
Younger Age as a Risk Factor for Gynecologic Cancer–related Lymphedema: A Systematic Review
Guliyeva G, Huayllani MT, Avila FR, Boczar D, Lu X, Forte AJ. Younger Age as a Risk Factor for Gynecologic Cancer–related Lymphedema: A Systematic Review. Anticancer Research 2020, 40: 6609-6612. PMID: 33288555, DOI: 10.21873/anticanres.14685.Peer-Reviewed Original ResearchConceptsGynecologic cancerLower limb lymphedemaYounger ageRisk factorsLimb lymphedemaCancer-related lymphedemaImpact of ageHazard ratioLymphedema developmentOdds ratioOutcome measuresEarly diagnosisSystematic reviewOlder ageLymphedemaCancerRelevant articlesIndividual studiesAgeTreatmentSignificant relationshipMorbidityRisk assessmentUnanticipated Uterine and Cervical Malignancy in Women Undergoing Hysterectomy for Uterovaginal Prolapse.
Andiman SE, Bui AH, Hardart A, Xu X. Unanticipated Uterine and Cervical Malignancy in Women Undergoing Hysterectomy for Uterovaginal Prolapse. Urogynecology 2020, 27: e549-e554. PMID: 33208657, DOI: 10.1097/spv.0000000000000990.Peer-Reviewed Original ResearchConceptsMultivariable logistic regressionUterovaginal prolapseUterine cancerCervical cancerSurgeons National Surgical Quality Improvement ProgramNational Surgical Quality Improvement ProgramSurgical Quality Improvement ProgramLogistic regressionUnexpected uterine malignancyQuality Improvement ProgramSample eligibility criteriaPathology-confirmed diagnosisUterine malignanciesRadical hysterectomyTotal hysterectomyPatient characteristicsUterine weightCervical malignancyGynecologic cancerOutcome measuresHysterectomyAmerican CollegeEligibility criteriaBivariate statistical testsConcurrent proceduresTea Consumption and Risk of Cancer: An Umbrella Review and Meta-Analysis of Observational Studies
Kim T, Jeong G, Yang J, Lee K, Kronbichler A, van der Vliet H, Grosso G, Galvano F, Aune D, Kim J, Veronese N, Stubbs B, Solmi M, Koyanagi A, Hong S, Dragioti E, Cho E, de Rezende L, Giovannucci E, Shin J, Gamerith G. Tea Consumption and Risk of Cancer: An Umbrella Review and Meta-Analysis of Observational Studies. Advances In Nutrition 2020, 11: 1437-1452. PMID: 32667980, PMCID: PMC7666907, DOI: 10.1093/advances/nmaa077.Peer-Reviewed Original ResearchConceptsTea consumptionUmbrella reviewCancer riskReduced risk of oral cancerMeta-analyses of observational studiesObservational studyAssociated with cancer riskMeta-analysis of observational studiesMeta-analysesSmall-study effectsRisk of oral cancerBetween-study heterogeneityOral cancerLevel of evidenceWell-designed prospective studiesSuggestive evidenceEffect sizeReduced riskMeta-analysisGynecologic cancerOrgan cancersBreast cancerConsumed beveragesProspective studyAssociation
2019
Fertility preservation in gynecologic cancers
Taylan E, Oktay K. Fertility preservation in gynecologic cancers. Gynecologic Oncology 2019, 155: 522-529. PMID: 31604663, DOI: 10.1016/j.ygyno.2019.09.012.Peer-Reviewed Original ResearchConceptsFertility preservationGynecologic cancerFertility-sparing surgical approachCancer survivorship careReproductive-age womenGynecologic malignanciesSurvivorship careSurgical approachTreatment optionsAge womenOvarian cancerNumber of womenCancerWomenReproductive technologiesSignificant proportionCurrent knowledgeReview articleMalignancyReproductive potentialCare
2018
Psychiatric Aspects of Obstetrics and Gynecology Patients
Ho P. Psychiatric Aspects of Obstetrics and Gynecology Patients. 2018, 235-263. DOI: 10.1007/978-3-319-99774-2_14.Peer-Reviewed Original ResearchPsychiatric conditionsGynecologic conditionsCommon gynecologic surgeryPolycystic ovarian diseaseCommon psychiatric disordersGynecologic patientsPerioperative periodUrinary incontinenceCervical dysplasiaGynecology patientsGynecologic cancerOvarian diseasePsychiatric comorbidityGynecologic surgeryOutpatient settingOutpatient procedurePelvic prolapseTreatment outcomesNonpsychiatric conditionsUterine leiomyomaTherapeutic approachesPsychiatric disordersPsychiatric aspectsPatientsSurgeryTargeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers
Lin ZP, Zhu YL, Ratner ES. Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers. Frontiers In Oncology 2018, 8: 303. PMID: 30135856, PMCID: PMC6092490, DOI: 10.3389/fonc.2018.00303.Peer-Reviewed Original ResearchCDK activityCell cycleDefective cell cycle regulationCyclin-dependent kinase activityCell cycle phase transitionCell cycle regulationCyclin-dependent kinasesNormal cell cycleHomologous recombination repairHallmarks of cancerTargeting Cyclin-Dependent KinasesSynthetic lethal approachCell cycle phasesSmall molecule inhibitorsGynecologic cancerCheckpoint activationPARP inhibitorsCycle regulationHR repairKinase activityRecombination repairDNA damaging modalitiesProtein targetsCDKMajor gynecologic malignancies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply